玻璃体内西罗莫司治疗非感染性葡萄膜炎:从临床前到临床研究的进展
本文综述了玻璃体内西罗莫司(一种mTOR抑制剂)治疗非感染性中间、后段及全葡萄膜炎的药代动力学、疗效与安全性。基于3项临床前研究和4项1-3期临床研究,440μg剂量在3期研究中使22.8%患者第5个月眼部炎症完全消退(优于44μg组的10.3%,P=0.025),且68.1%基线使用全身皮质激素者停用激素,未报告相关全身不良事件。
要点
- 临床前研究显示22-220μg玻璃体内西罗莫司在玻璃体持续释放≥2个月,全身浓度低于免疫抑制阈值。
- 3期研究显示440μg组第5个月炎症完全消退率22.8%,显著高于44μg组的10.3%(P=0.025)。
- 440μg组中68.1%基线使用全身皮质激素的患者在第5个月停用激素,且1-3期研究未报告相关全身不良事件。
核心结论
- 玻璃体内西罗莫司440μg可能成为治疗非感染性中间、后段及全葡萄膜炎的有效、耐受性好且节省皮质激素的抗炎选择。
研究设计与样本
- 综述汇总了3项临床前研究(兔)和4项1-3期临床研究(1期n=50和n=30,2期n=24,3期n=347)的药代动力学、疗效和安全性结果。
主要发现
- 兔临床前研究显示22-220μg玻璃体内西罗莫司在玻璃体中持续释放2个月或以上,全身浓度低于全身免疫抑制阈值(约8 ng/ml)。
- 2项1期研究(n=50和n=30)确立玻璃体内西罗莫司可改善人类眼部炎症。
- 2期和3期研究(n=24和n=347)提示440μg具有最佳获益-风险特征。
- 3期研究中440μg组第5个月眼部炎症完全消退比例为22.8%,显著高于44μg组的10.3%(P=0.025,Fisher精确检验)。
- 3期研究中基线使用全身皮质激素的69例患者中有47例(68.1%)在第5个月停用皮质激素。
关键数值与推荐
- 3期研究主要疗效指标:第5个月眼部炎症完全消退比例,440μg组22.8% vs. 44μg组10.3%(P=0.025)。
- 临床前研究全身浓度阈值:低于约8 ng/ml(全身免疫抑制阈值)。
临床怎么用
- 对于非感染性中间、后段及全葡萄膜炎,玻璃体内西罗莫司440μg可能作为局部抗炎和节省皮质激素的治疗选择。
- 治疗期间可考虑根据炎症反应和皮质激素使用情况评估疗效,1-3期研究显示未报告相关全身不良事件。
局限性
- 本文为综述,未报告各研究的盲法、随访时长、纳入排除标准等设计细节。
- 临床前数据来自兔模型,向人类外推需谨慎。
- 3期研究仅报告第5个月主要终点,长期疗效和安全性未在摘要中呈现。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In recent decades, the treatment paradigm for noninfectious intermediate uveitis, posterior uveitis, and panuveitis, a group of intraocular inflammatory diseases, has included systemic and local (periocular or intraocular) corticosteroids, biologics, and other steroid-sparing immunomodulatory therapy agents. Recently, an intravitreal formulation of sirolimus, an immunosuppressant that inhibits the mammalian target of rapamycin, a key regulator of cell growth in the immune system, was developed. On the basis of this mechanism and the local method of delivery, it was hypothesized that intravitreal sirolimus can improve ocular inflammation in patients with noninfectious intermediate uveitis, posterior uveitis, and panuveitis, with minimal systemic exposure and systemic adverse events (AEs). This review summarizes the pharmacokinetics, efficacy, and safety results of intravitreal sirolimus from 3 preclinical studies and 4 phase 1-3 clinical studies. Preclinical studies in rabbits showed that 22 to 220 μg intravitreal sirolimus results in sustained release of sirolimus in the vitreous for 2 months or more, with systemic concentrations below the threshold for systemic immunosuppression (approximately 8 ng/ml). Subsequently, 2 phase 1 studies (n = 50 and n = 30) established that intravitreal sirolimus improves ocular inflammation in humans. Further investigation in phase 2 and 3 studies (n = 24 and n = 347, respectively) suggested that 440 μg has the best benefit-to-risk profile. In the phase 3 study, the proportion of patients who showed complete resolution of ocular inflammation at month 5 was significantly higher in the 440-μg group than in the 44-μg group (22.8% vs. 10.3%; P = 0.025, Fisher exact test). In addition, 47 of 69 patients (68.1%) who were treated with systemic corticosteroids at baseline discontinued corticosteroid use at month 5. No sirolimus-related systemic AEs were reported in phase 1-3 studies. Collectively, these preclinical and clinical study data of intravitreal sirolimus support the therapeutic rationale of treating noninfectious uveitis with a local mammalian target of rapamycin inhibitor and suggest that 440 μg intravitreal sirolimus has the potential to be an effective and well-tolerated anti-inflammatory and corticosteroid-sparing treatment for noninfectious intermediate uveitis, posterior uveitis, and panuveitis.
引用
- Nguyen QD, Merrill PT, Sepah YJ, et al. Intravitreal Sirolimus for the Treatment of Noninfectious Uveitis: Evolution through Preclinical and Clinical Studies. Ophthalmology. 2018. PMID: 30060978. doi:10.1016/j.ophtha.2018.06.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。